Our Website Uses Cookies 

We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.

For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Lauren Pignataro Rakitin is a member of the firm’s corporate practice and is resident in our Washington, DC office. Her practice includes a broad range of corporate and transactional matters, including licensing and collaboration arrangements, strategic acquisitions and divestitures, manufacturing and supply agreements, and other commercial transactions.

Ms. Rakitin also has experience drafting and negotiating other commercial contracts in the life sciences and technology industries.

  • A global biopharmaceutical company in a collaboration, option and license agreement with a biotechnology company for the research and development of adeno-associated viruses—gene therapy delivery tools known as viral vectors—that shuttle genetic instructions into the brain to help treat Alzheimer’s and other neurodegenerative diseases.
  • A global biologics research and development company in an exclusive, worldwide out-license agreement with a clinical-stage biopharmaceutical company regarding a small molecule compound.
  • A global biopharmaceutical company in a novel collaboration, option and license agreement with a biotechnology company for the research and development of viral immunotherapies in oncology.
  • A medical research, discovery and development company in support of all aspects of its Phase 2 and Phase 3 clinical studies, including CRO arrangements, services agreements and clinical trial agreements.
  • A biotechnology research company in a collaboration agreement to develop a companion diagnostic to a clinical-stage drug candidate for the diagnosis and treatment of Alzheimer's.
  • Multiple innovator pharmaceutical companies in license agreements to settle Hatch-Waxman patent litigation.
  • A global pharmaceutical company in a co-promotion agreement regarding the U.S. and European promotion of a key portfolio drug.
  • Advised a German manufacturing technology company on its € 70 million international stock disposition and reorganization.
  • Represented a leading food and beverage company on its global redistribution of assets.

Pro Bono

  • Advised a District of Columbia nonprofit organization in its dissolution, including sales of major assets, real estate dispositions, debt settlements, and filings for dissolution.
  • Advised a District of Columbia nonprofit organization in its restructuring, including the transfer of membership interests in a related Maryland limited liability company.
  • Advised a New York nonprofit organization regarding maintaining 501(c)(3) status and receiving charitable contributions. 

Memberships and Affiliations

  • AnBryce Foundation, Advisory Council Member

Previous Experience

  • Associate at a New York law firm (2014-2015)